Acute myeloid leukemia recurrent represents one of the most challenging situations in cancer care, as the disease returns after treatment or fails to respond adequately to initial therapy, requiring new approaches to regain control and help patients maintain their quality of life.

Understanding Recurrent and Refractory Acute Myeloid Leukemia

When acute myeloid leukemia comes back after a period of remission, doctors call this a relapse or recurrent disease. The term relapse means that the leukemia has returned after treatment appeared to work and the person achieved remission. On the other hand, refractory acute myeloid leukemia describes a situation where the cancer never fully responded to the first treatment, meaning that chemotherapy drugs did not kill enough leukemia cells to achieve complete remission.^[3]

Both situations require additional treatment to try to reach complete remission again. The journey through recurrent or refractory disease can feel overwhelming and frightening for patients and their families. Understanding that there are multiple treatment options available, and that medical teams have experience managing these situations, can provide some measure of comfort during this difficult time.^[3]

A relapse can happen at different times after initial treatment. Most relapses occur within the first two years after finishing the initial therapy called induction treatment. As more time passes beyond treatment, relapses become less common. After five years, the chance of the disease coming back becomes extremely small.^[13]

How Relapse is Detected

Healthcare teams use several methods to determine if acute myeloid leukemia has returned. One way is by watching for symptoms, which might be similar to those experienced when first diagnosed. These symptoms can include bruises appearing easily on the skin, swollen glands in various parts of the body, persistent tiredness that doesn’t improve with rest, shortness of breath during normal activities, fever without an obvious infection, unexplained sweating especially at night, headaches, and aching bones throughout the body.^[7]

However, many conditions besides leukemia can cause these same symptoms. Because of this, doctors need to perform specific tests to confirm whether a relapse has actually occurred or if something else is causing the symptoms. Blood tests check the numbers of normal blood cells compared to leukemia cells in samples taken from a vein. Bone marrow tests remove a small sample from inside the bone to examine the number of leukemia cells present and to look for changes in genes within the cancer cells.^[7]

Sometimes doctors perform a procedure called a lumbar puncture, where they remove a small amount of fluid from around the spinal cord. This fluid is then checked for the presence of leukemia cells. Chest X-rays help doctors look for enlarged lymph nodes in the chest area. Your doctor will tell you that a relapse has occurred if the number of leukemia cells in your bone marrow has increased and you have fewer healthy cells in your blood.^[7]

Factors That Influence Treatment Decisions

When planning treatment for relapsed or refractory acute myeloid leukemia, healthcare teams consider several important factors. Your age plays a role because younger patients may be able to tolerate more intensive treatments compared to older individuals. Your overall health and how well your body is functioning also matters greatly. Someone who is physically strong may be able to handle aggressive chemotherapy, while someone with other health problems might need gentler approaches.^[3]

The length of time the leukemia was in remission before it came back is another crucial consideration. If the disease stayed away for a longer period, particularly more than one year, the same treatments used initially might work again. However, if the leukemia returns quickly after treatment, doctors often need to try different drugs or combinations.^[3]

The treatments you received before and how your body responded to them guide future treatment decisions. If certain chemotherapy drugs worked well initially but the disease eventually returned, doctors might use similar medications at different doses. Where the leukemia comes back in the body also influences the treatment plan. For example, if leukemia cells are found in the central nervous system, which includes the brain and spinal cord, special treatments may be needed to reach those areas.^[3]

Chemotherapy Options for Recurrent Disease

Chemotherapy remains the main treatment approach for relapsed or refractory acute myeloid leukemia. For some patients, especially if the complete remission lasted longer than one year, doctors may recommend repeating cycles of the same or similar drugs used during the initial induction treatment. These drugs may be given at similar doses or sometimes at higher doses to try to overcome the resistance the leukemia cells may have developed.^[3]

One commonly used approach is called the 7-and-3 protocol. In this treatment plan, a drug called cytarabine is given continuously for 7 days, while another type of medication called an anthracycline is given for 3 days. The anthracyclines that might be used include daunorubicin, doxorubicin, idarubicin, or mitoxantrone. This combination has been used for many years in treating acute myeloid leukemia.^[3]

Other chemotherapy combinations may be offered for relapsed or refractory disease. The FLAG regimen combines fludarabine, cytarabine, and filgrastim. The MEC protocol uses mitoxantrone, etoposide, and cytarabine together. Some patients receive high-dose cytarabine combined with mitoxantrone, while others might get high-dose etoposide with cyclophosphamide. Another option combines cytarabine, daunorubicin, and etoposide. A newer approach uses clofarabine and cytarabine, sometimes with or without filgrastim added.^[3]

Not everyone with relapsed or refractory acute myeloid leukemia is strong enough to receive intensive chemotherapy. For these individuals, doctors may offer less intensive chemotherapy regimens that are easier for the body to tolerate. These gentler options include azacitidine with or without venetoclax, decitabine with or without venetoclax, or clofarabine with or without cytarabine. These treatments can still help control the disease while causing fewer severe side effects.^[3]

Targeted Therapy Approaches

Targeted therapy uses drugs designed to attack specific molecules or proteins on cancer cells or inside them. These medications work differently than traditional chemotherapy because they specifically target features that are unique to cancer cells, potentially causing less damage to normal, healthy cells. For people with relapsed or refractory acute myeloid leukemia who are not strong enough for intensive chemotherapy, targeted therapy may be an important option.^[3]

If genetic testing shows that your acute myeloid leukemia has something called the FLT3 mutation, you may be treated with a drug called gilteritinib. This medication specifically blocks the abnormal protein created by the FLT3 mutation. Studies have shown that gilteritinib is well tolerated by patients and leads to improved outcomes compared with standard salvage therapy. Both the U.S. Food and Drug Administration and the European Medicines Agency have approved gilteritinib for this use.^[11]

For patients whose leukemia cells have mutations in genes called IDH1 or IDH2, specific inhibitor drugs are available. Ivosidenib targets the IDH1 mutation, while enasidenib works against the IDH2 mutation. These medications present well-tolerated options for refractory or relapsed disease, even in elderly patients and those who have received multiple previous treatments. Response rates with these drugs range from 30 to 40 percent. The FDA has approved both substances for relapsed or refractory acute myeloid leukemia patients with IDH1 or IDH2 mutations.^[11]

Another targeted therapy option involves a drug called gemtuzumab ozogamicin, which may be used if acute myeloid leukemia cells have a protein marker called CD33 on their surface. This medication attaches to the CD33 protein and delivers a toxic substance directly to the cancer cells, helping to destroy them while potentially sparing normal cells that don’t have this marker.^[3]

Stem Cell Transplantation

For patients who are physically fit and have not previously undergone the procedure, doctors often aim to perform a stem cell transplant after salvage therapy brings the leukemia back under control. A stem cell transplant, also called a bone marrow transplant, is currently the only established curative therapy for acute myeloid leukemia. First, patients receive high-dose chemotherapy to kill as many cancer cells as possible. Then they receive healthy stem cells from a donor to replace the blood-forming cells that the chemotherapy destroyed.^[2]

In patients with acute myeloid leukemia who experience a relapse after already having had a stem cell transplant and who still have good performance status, intensive therapy can be considered. This might be followed by cellular therapy such as donor lymphocyte infusion, where immune cells from the original donor are given to help fight the leukemia, or even a second stem cell transplant. However, these approaches are challenging, and fewer than 20 percent of these patients are alive after 5 years.^[11]

The timing of relapse matters greatly when considering another transplant. Relapse can be categorized as early or late, and this timing influences both the prognosis and the possibility of attempting another allogeneic hematopoietic stem cell transplantation. The overall prognosis for relapsed acute myeloid leukemia patients is generally poor but depends largely on these factors.^[11]

Treatment for Central Nervous System Involvement

Sometimes acute myeloid leukemia spreads to the central nervous system, which includes the brain and spinal cord. When this happens, special treatment approaches are needed because many drugs given through the bloodstream cannot easily reach these areas. The treatment typically includes chemotherapy given directly into the spinal fluid, a method called intrathecal chemotherapy. The drugs used for this type of treatment are usually methotrexate or cytarabine.^[3]

This medication is typically given during a lumbar puncture procedure, which is also sometimes called a spinal tap. During this procedure, a thin needle is carefully inserted between the bones of the lower spine to reach the space where spinal fluid circulates around the spinal cord and brain. The chemotherapy drug is then injected directly into this fluid, allowing it to travel throughout the central nervous system to reach leukemia cells that may be present there.^[3]

Managing Treatment When Intensive Therapy Isn’t Possible

For patients who are not fit enough to receive intensive chemotherapy, the therapeutic aim shifts to prolonging life while maintaining an acceptable quality of life. This approach recognizes that aggressive treatments may cause more harm than benefit in some situations, and that helping someone feel as well as possible for as long as possible becomes the priority.^[11]

Several options exist for these patients depending on what treatments they received initially. Hypomethylating agents, low-dose cytarabine, and therapy with hydroxyurea to reduce cell counts are possibilities. For patients who have not previously been treated with venetoclax in their first-line therapy, the combination of venetoclax with demethylating agents achieves encouraging response rates. Venetoclax is currently being studied in combination with intensive salvage therapy as well.^[11]

Living with Recurrent Acute Myeloid Leukemia

Receiving news that acute myeloid leukemia has relapsed or that treatment hasn’t worked as hoped is understandably very difficult. Patients often feel shocked, scared, or devastated by this information. If you are caring for someone you love who has acute myeloid leukemia, you might feel powerless during this challenging time. These feelings are completely normal and valid responses to a serious situation.^[13]

Despite the difficulties, many treatments remain available for refractory and relapsed acute myeloid leukemia. Support services exist to help patients and families cope with the emotional impact of a relapse. Speaking with healthcare teams about your situation, your concerns, and your goals for treatment can help ensure that the care you receive aligns with what matters most to you.^[13]

During treatment for recurrent disease, protecting yourself from infection becomes especially important. Your white blood cell count may drop significantly during treatment, making you more vulnerable to infections. Limiting visits from people, especially those who are sick, can help you recuperate both physically and mentally. Avoiding high-risk places such as crowded shopping centers reduces exposure to potential infections. Increased hygiene practices, such as frequent handwashing and avoiding touching your face, become second nature by the time treatment is finished.^[17]

Supportive Care and Quality of Life

Managing diet during treatment for recurrent acute myeloid leukemia plays an important part in coping with the disease and helping your body stay as strong as possible. Treatment can affect food preferences and appetite in various ways. You might experience loss of appetite, changes in how foods taste or smell, nausea, a sore mouth, or diarrhea. Finding high-calorie and high-protein drinks can help when eating solid food becomes difficult. Once treatment effects begin to improve, most people can gradually return to eating a normal diet, though this may take time after intensive treatment.^[14]

Physical activity, when possible, offers benefits both physically and emotionally during and after treatment for recurrent disease. The amount you can do depends on your fitness level and how you feel from day to day. You will likely experience days when energy is lower, and it’s important to listen to your body and build activity levels slowly. Gentle walking is suitable for most people to start with. Recent research suggests that regular exercise might help reduce tiredness and symptoms of depression after treatment for blood cancers like acute myeloid leukemia.^[14]

Emerging evidence demonstrates that early palliative care integration with standard leukemia care results in improved quality of life, better psychological outcomes, and greater participation in advance care planning. Palliative care focuses on relieving symptoms and stress regardless of the stage of illness, and it can be provided alongside treatments aimed at controlling the leukemia. This approach helps patients live as well as possible for as long as possible.^[16]